Citius Pharma Files Definitive Additional Proxy Materials
Ticker: CTXR · Form: DEFA14A · Filed: Jan 26, 2024 · CIK: 1506251
Complexity: simple
Sentiment: neutral
Topics: proxy-materials, corporate-governance, shareholder-meeting
TL;DR
**Citius Pharma just filed definitive proxy materials, get ready to vote on key company decisions.**
AI Summary
Citius Pharmaceuticals, Inc. filed a DEFA14A on January 26, 2024, indicating they are providing definitive additional materials related to a proxy statement. This filing is a standard procedural update for shareholders, confirming that the company is distributing final proxy materials for an upcoming shareholder meeting. For investors, this means Citius is moving forward with its corporate governance processes, and shareholders should expect to receive or have access to the full proxy statement detailing proposals to be voted on, which could include director elections, executive compensation, or other key corporate actions.
Why It Matters
This filing signals that Citius Pharmaceuticals is preparing for an upcoming shareholder meeting, where important corporate decisions will be made. Shareholders need to review the full proxy statement to understand what they will be voting on.
Risk Assessment
Risk Level: low — This is a routine administrative filing for proxy materials and does not inherently indicate new financial or operational risks.
Analyst Insight
Investors should look out for the full proxy statement from Citius Pharmaceuticals to understand the specific proposals and voting items for the upcoming shareholder meeting, as this DEFA14A is merely an announcement of additional materials.
Key Players & Entities
- Citius Pharmaceuticals, Inc. (company) — the registrant filing the DEFA14A
- 001-38174 (other) — SEC file number for Citius Pharmaceuticals
- January 26, 2024 (date) — date the DEFA14A was filed
FAQ
What is the purpose of Citius Pharmaceuticals, Inc.'s DEFA14A filing on January 26, 2024?
The DEFA14A filing by Citius Pharmaceuticals, Inc. on January 26, 2024, indicates that they are providing "Definitive Additional Materials" related to a proxy statement, as specified in the filing under 'Check the Appropriate Box'.
What type of SEC filing is this document?
This document is a DEFA14A, which stands for Definitive Additional Materials, as stated in the 'FORM TYPE' field and confirmed by the 'Check the Appropriate Box' section marking 'Definitive Additional Materials'.
Is Citius Pharmaceuticals, Inc. the registrant or a party other than the registrant in this filing?
Citius Pharmaceuticals, Inc. is the registrant, as indicated by the checked box 'Filed by the Registrant' next to their name in the 'SCHEDULE 14A INFORMATION' section.
Was a filing fee required for this DEFA14A?
No, a filing fee was not required for this DEFA14A, as indicated by the checked box 'No fee required' under the 'Payment of Filing Fee' section.
What is the business address of Citius Pharmaceuticals, Inc. as listed in the filing?
The business address of Citius Pharmaceuticals, Inc. is 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ 07016, with a business phone of (908) 967-6676, according to the 'BUSINESS ADDRESS' section of the filing.
Filing Stats: 125 words · 1 min read · ~1 pages · Grade level 20 · Accepted 2024-01-26 16:08:28
Filing Documents
- ea192112-defa14a_citius.htm (DEFA14A) — 8KB
- image_001.jpg (GRAPHIC) — 399KB
- image_002.jpg (GRAPHIC) — 265KB
- 0001213900-24-006978.txt ( ) — 924KB
From the Filing
ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the Appropriate Box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under Rule 14a-12 Citius Pharmaceuticals, Inc. (Name of Registrant as Specified in Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials: Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.